Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05230875
Other study ID # CHUBX 2021/16
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 7, 2022
Est. completion date September 5, 2023

Study information

Verified date September 2022
Source University Hospital, Bordeaux
Contact Pauline RIVIERE
Phone 0557656439
Email pauline.riviere@chu-bordeaux.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients with Inflammatory Bowel Disease (IBD) have higher rates of sexual dysfunction than the general population. We offer an educational program on IBD including a specific discussion on intimacy and sexuality for IBD patients. Our objective is to investigate the benefit of this intervention on sexual function in patients with IBD.


Description:

Patients with Inflammatory Bowel Disease (IBD) have higher rates of sexual dysfunction than healthy controls. No interventional study has addressed this matter so far. The aim of our study is to investigative the benefit of a psycho-educational intervention on sexual function in patients with IBD, by comparing patients participating to an educational program including a specific discussion on intimacy and sexuality to patients followed in usual care.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date September 5, 2023
Est. primary completion date September 5, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age > 18 years - Crohn's disease or Ulcerative Colitis diagnosed according to usual criteria - Participation to IBD educational program Exclusion Criteria: - Unability to read or write French - Patients without sexual activity for religious reasons

Study Design


Intervention

Behavioral:
self-administered questionnaire
All patients participating in the therapeutic education program will complete a self-administered questionnaire before participation in educational program. A new identical self-questionnaire will be distributed to patients 3 to 6 months after their participation in the therapeutic education program.

Locations

Country Name City State
France Centre Hospitalier Universitaire de Bordeaux Talence

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean scores of sexual function scores using International Index of Erectile Function (IIEF) for men before participation to educational program
Primary Mean scores of sexual function scores using International Index of Erectile Function (IIEF) for men from 3 to 6 months after participation to educational program.
Primary Mean scores of sexual function scores using Female Sexual Function Index (FSFI) for women. before participation to educational program
Primary Mean scores of sexual function scores using Female Sexual Function Index (FSFI) for women. from 3 to 6 months after participation to educational program.
Secondary Mean scores for quality of life (S-IBDQ) before participation to educational program
Secondary Mean scores for quality of life (S-IBDQ) from 3 to 6 months after participation to educational program.
Secondary Mean scores for anxiety and depression (HADS) before participation to educational program
Secondary Mean scores for anxiety and depression (HADS) from 3 to 6 months after participation to educational program.
Secondary Mean scores for fatigue (FSS) before participation to educational program
Secondary Mean scores for fatigue (FSS) from 3 to 6 months after participation to educational program.
Secondary Means score for body image (BIS). before participation to educational program
Secondary Means score for body image (BIS). from 3 to 6 months after participation to educational program.
See also
  Status Clinical Trial Phase
Recruiting NCT05702879 - Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
Not yet recruiting NCT05953402 - A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT03950232 - An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT03124121 - Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Phase 4
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Withdrawn NCT04209556 - A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Recruiting NCT04398550 - SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis N/A
Recruiting NCT04314375 - Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis Phase 4
Active, not recruiting NCT04857112 - Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis Phase 2
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Active, not recruiting NCT04033445 - A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Active, not recruiting NCT06221995 - Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
Recruiting NCT04767984 - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Phase 2
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Recruiting NCT06071312 - FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach Phase 1/Phase 2
Completed NCT03760003 - Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis Phase 2
Not yet recruiting NCT05539625 - Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis Phase 2